Whitehawk Therapeutics (WHWK) Assets Average (2011 - 2026)

Whitehawk Therapeutics (WHWK) has reported Assets Average for 16 consecutive years, with $139.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average fell 8.63% year-over-year to $139.0 million; the TTM figure through Mar 2026 stood at $139.0 million (down 8.63% YoY), while the FY2025 annual figure was $110.6 million, up 9.08% from the prior year.
• Assets Average declined to $139.0 million in Q1 2026 per WHWK's latest filing, from $158.9 million in the prior quarter.
• Across five years, Assets Average topped out at $207.4 million in Q2 2025 and bottomed at $78.0 million in Q4 2024.
• Historically, Assets Average has averaged $146.3 million across 5 years, with a median of $150.1 million in 2022.
• Annual changes were most pronounced in 2022 — Assets Average soared 400.5% — and 2024, when it sank 42.66%.
• Whitehawk Therapeutics' Assets Average stood at $189.2 million in 2022, then fell by 28.09% to $136.0 million in 2023, then sank by 42.66% to $78.0 million in 2024, then soared by 103.73% to $158.9 million in 2025, then retreated by 12.52% to $139.0 million in 2026.
• Business Quant data shows WHWK's Assets Average at $139.0 million in Q1 2026, $158.9 million in Q4 2025, and $173.9 million in Q3 2025.